YANTAI, China, Aug. 27, 2024 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments.

During the reporting period, the company's total revenue was RMB 363 million, up 39% year-over-year. In this, the revenue from product sales was RMB 332 million, up 28% year-over-year. The company was able to break even in this period, generating a net profit of RMB 61.67 million, up RMB 180 million from the previous period, with a net profit margin of 17%.

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here